ArticleNature communications2023
NIR-dye bridged human serum albumin reassemblies for effective photothermal therapy of tumor.
Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 82 citations in OpenAlex.
- Kinetic assembly tuning NIR-II cyanine aggregated states: Remarkable photothermal-mediated sustained retention in orthotopic hepatoma.Science advances · 2026Article
- Preparation of ENBSe-based photoredox catalysts for ONature protocols · 2026Review
- Integrated precise temperature regulation and electrophysiology sensing system for nanoplasmonic photothermal cardiac bradyarrhythmia therapy.Microsystems & nanoengineering · 2026Article
- Review
- PSMA-targeted fluorescent probe for NIR-II imaging in prostate cancer intraoperative navigation and tumor margin mapping.Theranostics · 2026Article
- Advances in cold atmospheric plasma therapy for cancer.Bioactive materials · 2025Review
- A Needle-Like HAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Albumin Encapsulation of Cyanine Dye for High-Performance NIR-II Imaging-Guided Photodynamic Therapy.Chemical & biomedical imaging · 2025Article
- Design and Characterization of Peptide-Conjugated Solid Lipid Nanoparticles for Targeted MRI and SPECT Imaging of Breast Tumors.ACS omega · 2025Article
- Long-term in vivo immune tracking nanoplatform based on AgBMC biology · 2025Article
- Photo-thermoresponsive polypyrrole-crosslinked single-chain nanoparticles for photothermal therapy.Communications chemistry · 2025Article
- A new NCL-targeting aptamer-drug conjugate as a promising therapy against esophageal cancer.Journal of nanobiotechnology · 2025Article
- Engineered hypoxia-responsive albumin nanoparticles mediating mitophagy regulation for cancer therapy.Nature communications · 2025Article
- Reduction-Responsive Nanoparticles Self-Assembled from Sericin-ss-Doxorubicin Conjugate for Hydrophobic IR780 Delivery with Integration of Antitumor Chemo-Phototherapy.International journal of nanomedicine · 2025Article
- Facile construction of manganese-based contrast agent with highRegenerative biomaterials · 2025Article
- Development of Cytolytic Iridium-Complexed Octaarginine Peptide Albumin Nanomedicine for Hepatocellular Carcinoma Treatment.International journal of nanomedicine · 2025Article
- Highly stable and near-infrared responsive phase change materials for targeted enzyme delivery toward cancer therapy.Materials today. Bio · 2024Article
- Rebooting the Adaptive Immune Response in Immunotherapy-Resistant Lung Adenocarcinoma Using a Supramolecular Albumin.Small (Weinheim an der Bergstrasse, Germany) · 2024Article
- Human Serum Albumin-CoatedAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- NIR laser-activated phthalocyanine loaded lipid nanoparticles targeting M2 macrophage for improved photoacoustic imaging-guided photothermal therapy.Materials today. Bio · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human serum albumin (HSA) based drug delivery platforms that feature desirable biocompatibility and pharmacokinetic property are rapidly developed for tumor-targeted drug delivery. Even though various HSA-based platforms have been established, it is still of great significance to develop more efficient preparation technology to broaden the therapeutic applications of HSA-based nano-carriers. Here we report a bridging strategy that unfastens HSA to polypeptide chains and subsequently crosslinks these chains by a bridge-like molecule (BPY-Mal
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.